Why Is PepGen Inc. (PEPG) Stock Down -64% Today?
Key Takeaways
- PEPG shares are down approximately 64% in intraday trading on March 31, 2026, from a prior close of $4.23 to roughly $1.52, building on steep after-hours losses recorded on March 30
- The primary catalyst is deeply disappointing Phase 2 clinical trial data from the FREEDOM2-DM1 study of PGN-EDODM1, PepGen's lead asset for myotonic dystrophy type 1 (DM1) — the drug showed virtually no benefit over placebo at the tested dose
- The 5 mg/kg cohort delivered a mean splicing correction of only 7.3% versus 6.8% for placebo, failing to establish a clinically meaningful efficacy signal
- The move extends a months-long collapse that began when the U.S. FDA placed a partial clinical hold on the FREEDOM2 trial in early March 2026
- Volume is dramatically elevated as institutional and retail investors exit positions following the data readout
- Traders are now focused on data from the higher 10 mg/kg cohort, anticipated in the second half of 2026
Opening Summary
PepGen Inc. (PEPG) is a Boston-based clinical-stage biotechnology company developing next-generation oligonucleotide therapeutics for severe neuromuscular and neurological diseases. Shares plummeted approximately 64% in Tuesday's session, trading near $1.52 after closing at $4.23 on Monday, March 30. The violent selloff was triggered by the release of Phase 2 clinical data showing PEPG's lead drug candidate failed to demonstrate meaningful efficacy compared to placebo in a key dose cohort, shattering investor hopes for the company's most advanced program.
Disappointing Phase 2 Trial Data
The central driver behind today's collapse is data from the 5 mg/kg dose cohort of the FREEDOM2-DM1 Phase 2 trial of PGN-EDODM1, PepGen's investigational treatment for myotonic dystrophy type 1 — a hereditary neuromuscular condition marked by progressive muscle weakness and wasting. The results were stark: the treatment arm achieved a mean splicing correction of just 7.3%, barely above the 6.8% observed in the placebo group — a difference that fails to establish clinical benefit. No meaningful improvements were recorded in functional endpoints including the 10-meter walk/run test or handgrip strength at this dose level.
PepGen attempted to contextualize the results by noting that a single outlier patient negatively skewed the overall figures; excluding that patient, the mean splicing correction rises to 22.9%. However, markets dismissed this framing as insufficient to rescue the data readout. The drug was generally well-tolerated with no serious adverse events reported, but tolerability alone is far from enough to satisfy investors who had been anticipating clear clinical separation from placebo.
Compounding FDA Regulatory Pressure
Today's data disaster does not occur in a vacuum. On March 4, 2026, PepGen disclosed that the U.S. FDA placed a partial clinical hold on the FREEDOM2 trial in the United States, citing concerns regarding preclinical pharmacology and toxicology studies previously submitted by the company. While the hold did not stem from patient-level safety signals, it halted U.S. enrollment and sent shares plunging more than 18–26% in the days that followed. The company received regulatory clearance to continue dosing in the UK, Canada, South Korea, Australia, and New Zealand, providing a limited operational lifeline.
By the time Monday evening's trial data hit the wire, PEPG had already shed significant ground from its prior levels. The combination of a live FDA hold and an efficacy miss at the 5 mg/kg dose created a compounding negative narrative that overwhelmed any residual optimism.
Market Context and Trading Activity
Trading volume in PEPG surged far above its average as the session progressed, consistent with institutional exits and panic selling following a binary clinical event. The broader biotechnology sector, tracked through funds such as XBI and IBB, did not see a comparable broad decline, confirming that today's move is stock-specific rather than a sector-wide rotation. The drop follows after-hours trading on March 30 that already priced in a 40%+ decline, meaning Tuesday's regular-session losses extend and deepen those initial reactions as more market participants process the clinical implications. With the stock now well below all key moving averages and trading in historically distressed territory, technical support levels have been decisively broken.
Trending AI Robots
For traders navigating high-volatility events like this one, Tickeron's Trending AI Robots page offers a curated view of the platform's best-performing automated trading bots under current market conditions. Tickeron hosts hundreds of AI-powered bots covering thousands of tickers across strategies, timeframes, and asset classes — but only those demonstrating the strongest real-time performance metrics are featured in the Trending section. Bots range from short-term momentum-based approaches to longer-term trend-following systems, each with transparent performance histories. Investors and active traders looking to bring a systematic, data-driven edge to volatile market environments may find value in exploring what Tickeron's AI infrastructure currently has to offer.
What Comes Next for PEPG
The immediate question hanging over PEPG is whether the higher 10 mg/kg dose cohort in the FREEDOM2-DM1 study — results of which are expected in the second half of 2026 — can deliver the efficacy that the 5 mg/kg arm failed to show. The company has stated it has sufficient cash to fund operations into the second half of 2027, removing near-term liquidity concerns and providing runway to pursue the higher-dose readout. However, investors will weigh whether the company's scientific thesis remains intact given the complete absence of a dose-response signal at the lower dose.
The FDA partial clinical hold on U.S. enrollment also remains unresolved, and the timeline for a potential lift is unclear. Analysts' consensus price targets, which stood at roughly $10–$12 prior to recent developments, will almost certainly face sharp downward revisions. Any legal proceedings related to alleged securities violations — investigations of which were publicly initiated by at least one law firm following earlier disclosures — represent an additional overhang. Traders should watch for any formal company response to today's data, as well as communication regarding the FDA hold resolution process.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
PEPG sees MACD Histogram just turned negative
PEPG saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on August 28, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 39 instances where the indicator turned negative. In 36 of the 39 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PEPG as a result. In 69 of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
PEPG moved below its 50-day moving average on September 24, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for PEPG crossed bearishly below the 50-day moving average on September 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PEPG declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PEPG entered a downward trend on September 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 15 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +2.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where PEPG advanced for three days, in 196 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
PEPG may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.501) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. PEPG’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PEPG’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement